Capecitabine in Low Risk Triple Negative Breast Cancer

Inclusion Criteria

• •1. Male and female patients aged ≥18 years;
• •2. Pathological confirmed of stage I breast cancer: histologically confirmed that the longest diameter of invasive cancer is no more than 2cm and the lymph node is negative (N0);
• •3. Histologically documented TNBC after early breast cancer surgery (absence of HER2, ER, and PR expression)
• •4. Patients who have undergone standard and adequate surgical treatment;
• •5. Has adequate organ function meeting the following criteria: (1) adequate bone marrow function: hemoglobin ≥ 90 g/L (no blood transfusion within 14 days); absolute neutrophil count ≥ 1.5 x 109 /L; platelet count ≥ 100 \* 109 /L; (2)adequate liver and kidney function: Alanine Aminotransferase (ALT) ≤ 3×upper limit of normal (ULN), Aspartate Aminotransferase (AST) ≤ 3×ULN, Total Bilirubin (TBIL)≤ 1.5×ULN, serum creatinine ≤ 1×ULN#and with endogenous creatinine clearance rate of \>50 ml/min (Cockcroft-Gault formula);
• •6. No evidence of metastasis in clinical or imaging examinations before surgery, that is, M0;
• •7. ECOG score of 0 or 1;
• •8. Meeting one of the low-risk criteria defined in this study: a) IM subtype, that is, the proportion of stromal tumor-infiltrating lymphocytes is high or CD8 is high; b) LAR subtype and ki-67 less than 20%; c) Age ≥ 70 years.
• •8)The patient voluntarily joined the study, signed the informed consent form, had good compliance, and cooperated with the follow-up.